Diagnostic Testing Market (By Type: Clinical Diagnostic, Home Diagnostic; By Application: Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, Odontology, Others; By Approach; By Solution; By Technology; By Mode of Testing; By Sample Type; By Testing Type; By Age; By Distribution Channel; By End User)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030
The global Diagnostic Testing market size was estimated at USD 165.58 billion in 2021 and is expected to surpass around USD 348.75 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.63% during the forecast period 2022 to 2030.
The realm of biomedical research, diagnostic tests are regarded as a useful tool for the early diagnosis of disease. Additionally, they aid in distinguishing between cancer in adults and cancer in children. In order to increase the rate of early detection and diagnosis of the disease that is preventable at an early stage among chronic and non-chronic disease as well, diagnostic tests are used in basic cancer research and drug development. This leads to the adoption of new therapies, patient specific therapies, and personalised medicine.
Increased prevalence of chronic disease, an increase in IVD tests worldwide, adequate reimbursement policies, an improvement in diagnosis seeking rates worldwide, and an expansion of molecular diagnostics are all contributing to the growth of the diagnostic tests market. However, factors such as high kit costs, a lack of relevant and appropriate kits, and a shortage of skilled laboratory personnel may restrain the market's expansion during the period of forecasting.
Due to rising public awareness and actions taken by the government and other authorities in this area, the diagnostic testing market has seen extraordinary penetration in developed economies in North America.
Report Scope of the Diagnostic Testing Market
Market Size in 2022
USD 179.87 Billion
Market Size by 2030
USD 348.75 Billion
Growth Rate from 2022 to 2030
CAGR of 8.63%
2022 to 2030
Type, Application, Approach, Solution, Technology, Mode of Testing, Sample Type, Testing Type, Age, Distribution Channel, End User, Geography
F-Hoffman La-Rcohe Ltd. (Switzerland), Danaher (US), BD (US), Thermo Fisher Scientific Inc. (US), ACON Laboratories Inc. (US), Hemosure, Inc. (US), MicroGen Diagnostics (US), Grifols, S.A (Spain), BODITECH MED INC. (South Korea), Chembio Diagnostic Systems, Inc. (US), Nanoentek (South Korea), DiaSorin S.p.A. (Italy), Bio-Rad Laboratories, Inc. (US), BIOMEDOMICS INC (US), EKF Diagnostics Holdings plc (UK), Siemens Healthcare GmbH (Germany), PerkinElmer Inc. (US), bioMérieux SA (France), ARKRAY USA, Inc. (US), Biohit Oyj (Finland), Quidel Corporation (US), Illumina, Inc. (US)
At order to diagnose or identify any illness or other medical disorders, clinical diagnostics encompasses all medical tests carried out in a pathology lab, diagnostic centre, hospital, or any other type of medical institution. These tests aid in the early identification of diseases and the identification of risk factors linked to such diseases, providing chances for both prevention and therapy. The rise in sedentary-related illnesses including diabetes, cardiovascular disease, high blood pressure, and lipid disorders, among others, is what motivates the development of clinical diagnostic tests. Additionally, it is anticipated that the number of patients with cancer and chronic renal disease would rise in the next years, propelling the market for clinical diagnostics. Additionally, advantages related to clinical diagnostics are predicted to drive the market through 2026, including rapid test results, simple testing procedures, simplicity of obtaining samples, and reduced discomfort.
Home diagnostics, often known as at-home diagnostics, allows patients or users to do various tests on-site at their homes. These test kits are often used to monitor an existing medical condition, identify a medical disease that has gone undetected, or provide information about a person's specific health characteristics.
The diagnostic tests market is divided into molecular diagnostic tools, in-vitro diagnostic tools, and point-of-care testing tools based on technique. Since in-vitro diagnostics are increasingly used to test samples like blood and saliva to diagnose illnesses or other disorders, the in-vitro diagnostic instrument sector is predicted to dominate the market. Additionally, the frequency of infectious and chronic illnesses is anticipated to rise during the projection period along with the ongoing expansion in the senior population.
The global response to the pandemic has been greatly aided by molecular diagnostic testing for COVID-19. Government agencies from all around the world are assisting laboratories in expediting COVID-19 testing procedures since testing is still an essential step in slowing the disease's fast spread. Accordingly, regulatory agencies used techniques to hasten the licencing of molecular diagnostic tools. As diagnostic testing continues to be the foundation of the COVID-19 response, supporting containment efforts to reduce the outbreak, significant corporations have also made strategic innovations to deploy COVID-19 quick tests and neutralise the influence of COVID-19 on their operating capabilities. Additionally, due to the severity of the crisis and growing capacity problems with PCR-based testing, diagnostic solutions were developed more quickly to fulfil the need for mass testing.
The diagnostic tests market is divided into categories based on application, including cardiology, oncology, neurology, orthopaedics, gastrointestinal, gynaecology, odontology, and others. Due to the global rise in heart patients and other cardiovascular disorders, the cardiology segment is predicted to dominate the market. The majority of cardiovascular disorders require diagnostic testing in order to be identified and treated. Cardiovascular diagnostic testing can reveal details about the electrical activity of the heart, the rhythm of the heartbeat, the efficiency with which blood pumps through the heart's chambers and valves, the ease with which blood flows through the coronary arteries to the heart muscle, and the presence of tumours or structural abnormalities in the cardiovascular system. The risk factors for heart disease are found via laboratory testing. These include the measurement of blood lipids such as LDL, HDL, and triglycerides as well as fats, cholesterol, and lipid components. For the diagnosis of diabetes, blood sugar and glycosylated haemoglobin levels are tested.
End User Insights
The diagnostic tests market is divided into hospitals, diagnostic centres, research laboratories and institutes, research institutions, homecare, blood banks, specialised clinics, ambulatory surgery centres, and others based on the end user. As hospitals perform a variety of diagnostic tests, including glucose tests, infectious diseases tests, cytology tests, CBC tests, blood culture tests, syphilis tests, urea tests, C-reactive protein tests, antigen tests, and HBA1C tests, causing for the detection and treatment of serious diseases or other major conditions, the hospitals segment is anticipated to dominate the market.
The market for diagnostic tests is dominated by North America due to the region's growing elderly population. According to the Centers for Condition Control and Prevention (CDC), six out of ten individuals in the United States have at least one chronic disease, and four out of ten persons have two or more. The top causes of mortality and disability in the United States are chronic illnesses like cancer, heart disease, and diabetes, which also account for the majority of the USD 3.8 trillion in yearly health care expenses. As a result, there is now a greater need in the United States for better care that is managed effectively. Therefore, it is anticipated that the rising incidence of infectious and chronic illnesses as well as increased recognition of the importance of laboratory testing will drive market expansion in the nation.
Due to the availability of affordable diagnostic tests for chronic illnesses in the area, Asia-Pacific (APAC) is anticipated to have considerable growth during the forecast period of 2022 to 2030.
Some of the prominent players in the Diagnostic Testing Market include:
- F-Hoffman La-Rcohe Ltd. (Switzerland)
- Danaher (US)
- BD (US)
- Thermo Fisher Scientific Inc. (US)
- ACON Laboratories Inc. (US)
- Hemosure, Inc. (US)
- MicroGen Diagnostics (US)
- Grifols, S.A (Spain)
- BODITECH MED INC. (South Korea)
- Chembio Diagnostic Systems, Inc. (US)
- Nanoentek (South Korea)
- DiaSorin S.p.A. (Italy)
- Bio-Rad Laboratories, Inc. (US)
- BIOMEDOMICS INC (US)
- EKF Diagnostics Holdings plc (UK)
- Siemens Healthcare GmbH (Germany)
- PerkinElmer Inc. (US)
- bioMérieux SA (France)
- ARKRAY USA, Inc. (US)
- Biohit Oyj (Finland)
- Quidel Corporation (US)
- Illumina, Inc. (US)
- Lamdagen Corporation (US)
- LifeSign LLC. (US)
- Medixbiochemica (Finaland)
- Nova Biomedical (US)
- Ortho Clinical Diagnostics (US)
- Sannuo Biosensing Co., Ltd. (US)
- STRECK (US)
- Sysmex Corporation (Japan)
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Diagnostic Testing market
- Clinical Diagnostic
- Home Diagnostic
- Molecular Diagnostic Instrument
- In-Vitro Diagnostic Instrument
- Point Of Care Testing Instrument
- Next-generation Sequencing
- Substrate Technology
By Mode of Testing
- Prescription Based Testing
- OTC Testing
By Sample Type
By Testing Type
- Adult & Geriatric
By Distribution Channel
- Direct Tenders
- Retail Sales
- Online Sales
By End User
- Hospitals, Diagnostic Center
- Research Labs and Institutes
- Research Institute
- Blood Banks
- Specialty Clinics
- Ambulatory Surgical Centers
- United Kingdom
- Rest of Europe